Efficacy and Safety Profile Evaluation of Acarbose Alone and in Association With Other Antidiabetic Drugs: A Systematic Review

Clinical Therapeutics

Volumn 34, Issue 6, 2012, Pages 1221-1236

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

glucosidase inhibitors; Acarbose; Combination therapy; Glycemic control; Postprandial hyperglycemia

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; CELL ADHESION MOLECULE; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ADD ON THERAPY; ANTIDIABETIC ACTIVITY; ARTERIAL WALL THICKNESS; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FLUID RETENTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN TREATMENT; INTERVENTION STUDY; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

ACARBOSE; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84862122513     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.04.012     Document Type: Review

References (67)

1. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
2. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. Action to Control Cardiovascular Risk in Diabetes Study Group.
3. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. ADVANCE Collaborative Group.
4. Skyler J.S., Bergenstal R., Bonow R.O., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and the VA diabetes trials. Diabetes Care 2009, 32:187-192. American Diabetes Association; American College of Cardiology Foundation; American Heart Association.
5. Standards of medical care in diabetes: 2012. Diabetes Care 2012, 35:S11-S63. American Diabetes Association.
6. Derosa G., Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technol Ther 2010, 12:491-501.
7. Derosa G., Tinelli C., Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab 2009, 11:1091-1099.
8. Derosa G., Maffioli P. GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. Curr Clin Pharmacol 2012 Mar 20, [Epub ahead of print].
9. Derosa G., Putignano P., Bossi A.C., et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol 2011, 666:251-256.
10. Derosa G., Maffioli P., Salvadeo S.A., et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010, 59:887-895.
11. Derosa G., Maffioli P. Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther 2012, 14:350-364.
12. Bailey C.J., Turner R.C. Metformin. N Engl J Med 1996, 334:574-583.
13. DeFronzo R., Goodman A. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995, 333:541-549. Multicenter Metformin Study Group.
14. Groop L. Sulfonylureas in NIDDM. Diabetes Care 1992, 15:737-747.
15. Malaisse W.J. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2003, 2:401-414.
16. Van de Laar F.A., Lucassen P.L., Akkermans R.P., et al. α-Glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005, 2. CD003639.
17. Krentz A.J., Bailey C.J. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005, 65:385-411.
18. Yki-Jarvinen H. Drug therapy: thiazolidinediones. N Engl J Med 2004, 351:1106.
19. Singh S., Loke Y.K., Furberg C.D. Thiazolidinediones and heart failure: a teleoanalysis. Diabetes Care 2007, 30:2248-2254.
20. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
21. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
22. Buse J.B., Henry R.R., Han J. Effects of exenatide on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2005, 27:2628-2635. Exenatide-113 Clinical Study Group.
23. Heine R.J., Van Gaal L.F., Johns D. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 2005, 143:559-569. GWAA Study Group.
24. Buse J.B., Rosenstock J., Sesti G. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47. LEAD-6 Study Group.
25. DURATION-6 top-line study results announced Eli Lilly and Co., Accessed March 3, 2011. http://newsroom.lilly.com/releasedetail.cfm?releaseid=554248.
26. Raz I., Hanefeld M., Xu L. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006, 49:2564-2571. Sitagliptin Study 023 Group.
27. Goldstein B.J., Feinglos M.N., Lunceford J.K. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30:1979-1987. Sitagliptin 036 Study Group.
28. Richter B., Bandeira-Echtler E., Bergerhoff K., Lerch C.L. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008, 2. CD006739.
29. Bonora E., Corrao G., Bagnardi V., et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006, 49:846-854.
30. Shiraiwa T., Kaneto H., Miyatsuka T., et al. Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care 2005, 28:2806-2807.
31. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001, 161:397-405. DECODE Study Group; European Diabetes Epidemiology Group.
32. Bell D.S., O'Keefe J.H., Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events?. Endocr Pract 2008, 14:112-124.
33. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat?. Diabetes 2005, 54:1-7.
34. Wolffenbuttel B.H.R., Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care 1999, 22:463-467. Dutch and German Repaglinide Study Group.
35. Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010, 70:1945-1961.
36. Derosa G., Salvadeo S.A. Risk management in the treatment of type 2 diabetes with pioglitazone. Diabetes Metab Syndr Obes 2009, 2:51-60.
37. Derosa G., Salvadeo S.A. Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. Curr Clin Pharmacol 2008, 3:77-84.
38. Derosa G., Salvadeo S.A. Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. Core Evid 2008, 2:189-198.
39. Derosa G. Pioglitazone plus glimepiride: a promising alternative in metabolic control. Int J Clin Pract Suppl 2007, 153:28-36.
40. Derosa G., Maffioli P. Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2011, 4:263-271.
41. Dickersin K., Scherer R., Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994, 309:1286-1291.
42. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of randomized controlled trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
43. Derosa G., Maffioli P., D'Angelo A., et al. Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study. J Diabetes Complications 2011, 25:258-266.
44. Derosa G., Maffioli P., Ferrari I., et al. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. Eur J Pharmacol 2011, 651:240-250.
45. Koyasu M., Ishii H., Watarai M., et al. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: a one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease. Clin Ther 2010, 32:1610-1617.
46. Hoffmann J., Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients: the Essen Study. Diabetes Care 1994, 17:561-566.
47. Hoffmann J., Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 1997, 103:483-490.
48. Pan C., Yang W., Barona J.P., et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008, 25:435-441.
49. Halimi S., Le Berre M.A., Grangé V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract 2000, 50:49-56.
50. Willms B., Ruge D. Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med 1999, 16:755-761.
51. Derosa G., Salvadeo S.A., D'Angelo A., et al. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr Med Res Opin 2009, 25:607-615.
52. Josse R.G. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial. Diabetes Res Clin Pract 1995, 28:S167-S172.
53. Mori Y., Shiozaki M., Matsuura K., et al. Evaluation of efficacy of acarbose on glucose fluctuation and postprandial glucose using continuous glucose monitoring in type 2 diabetes mellitus. Diabetes Technol Ther 2011, 13:467-470.
54. Su J.B., Wang X.Q., Chen J.F., et al. Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose. Chin Med J (Engl) 2011, 124:144-147.
55. Gerich J.E. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003, 163:1306-1316.
56. Kim M.K., Suk J.H., Kwon M.J., et al. Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes. Diabetes Res Clin Pract 2011, 92:322-328.
57. Derosa G., D'Angelo A., Salvadeo S.A., et al. Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. Biomed Pharmacother 2009, 63:723-733.
58. Derosa G., Mereu R., D'Angelo A., et al. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. J Clin Pharm Ther 2010, 35:565-579.
59. Ochiai H., Ooka H., Shida C., et al. Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes. Endocr J 2008, 55:549-556.
60. Chiasson J.L., Josse R.G., Gomis R. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077. STOP-NIDDM Trial Research Group.
61. Chiasson J.L., Josse R.G., Gomis R. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-494. STOP-NIDDM Trial Research Group.
62. Acarbose Cardiovascular Evaluation Trial (ACE), Accessed May 3, 2011. http://clinicaltrials.gov/ct2/show/NCT00829660.
63. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
64. Karpe F., Steiner G., Uffelman K., et al. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994, 106:83-97.
65. Matsumoto K., Sera Y., Abe Y., et al. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Prado 2004, 64:225-228.
66. Cominacini L., Fratta Pasini A., Garbin U., et al. Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia 1995, 38:1122-1124.
67. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296:2572-2581.